+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bone lead, hypertension, and lead nephropathy

Bone lead, hypertension, and lead nephropathy

Environmental Health Perspectives 78: 57-60

There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6 micrograms/g wet weight) and approximated levels found in lead workers (30 micrograms/g). At present, the most reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-ray-induced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead, which should find widespread application as a diagnostic tool and for epidemiologic studies.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 039415096

Download citation: RISBibTeXText

PMID: 3203647

DOI: 10.2307/3430500

Related references

Interrelationships of urinary lead after DMSA challenge, bone lead burden, and blood lead in lead exposed workers. Veterinary & Human Toxicology 36(4): 363, 1994

Bone lead and the diagnosis of lead nephropathy. Contributions to Nephrology 64: 102-108, 1988

Study of the relationships between bone lead levels and its variation with time and the cumulative blood lead index, in a repeated bone lead survey. Journal of Environmental Monitoring 2(3): 271-276, 2000

Bone lead level prediction models and their application to examine the relationship of lead exposure and hypertension in the Third National Health and Nutrition Examination Survey. Journal of Occupational and Environmental Medicine 51(12): 1422-1436, 2009

Comparison of lead bioavailability in F344 rats fed lead acetate, lead oxide, lead sulfide, or lead ore concentrate from Skagway, Alaska. Journal of Toxicology and Environmental Health 39(1): 79-93, 1993

Lead in bone II: skeletal-lead content as an indicator of lifetime lead ingestion and the social correlates in an archaeological population. American Journal of Physical Anthropology 55(3): 285-291, 1981

Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environmental Health Perspectives 115(3): 483-492, 2007

Past occupational exposure to lead: association between current blood lead and bone lead. Archives of Environmental and Occupational Health 62(4): 183-186, 2007

Melatonin reduces lead levels in blood, brain and bone and increases lead excretion in rats subjected to subacute lead treatment. Toxicology Letters 233(2): 78-83, 2015

Clinical applications of L-line X-ray fluorescence to estimate bone lead values in lead-poisoned young children and in children, teenagers, and adults from lead-exposed and non-lead-exposed suburban communities in the United States. Toxicology and Industrial Health 13(2-3): 211-218, 1997

Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study. American Journal of Epidemiology 153(2): 164-171, 2001

Serum (plasma) lead, blood lead, and bone lead. American Journal of Industrial Medicine 32(3): 319-320, 1997

Lead nephropathy, gout, and hypertension. American Journal of the Medical Sciences 305(4): 241-247, 1993

Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney International 41(5): 1192-1203, 1992